Project Grant HU00011010008

This Project Grant award of $613,585.00 from the Defense Health Agency (DHA) supports research by James Cook University's Australian Institute of Tropical Health and Medicine to develop point-of-injury intranasal drug therapies to reduce secondary injury and improve outcomes for individuals with traumatic brain injuries (TBIs) in civilian and military resource-limited environments. This research falls under the DHA's Military Medical Research and Development program (CFDA 12.420), which...

This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,086,750.00 to the Lovelace Biomedical Research Institute to support a research study on "A NOVEL ADVANCED RESUSCITATION FLUID FOR A SWINE POLYTRAUMA MODEL (TRAUMATIC BRAIN INJURY AND HEMORRHAGIC SHOCK)". The award, effective June 1, 2024 through May 31, 2026, will enable Lovelace Biomedical Research Institute, a non-profit preclinical contract...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding the development of an innovative portable device to rapidly detect and monitor traumatic brain injury (TBI) biomarkers. The $332,122 award to Hemex Health Inc. aims to create a point-of-care diagnostic platform that can quickly analyze whole blood samples to identify elevated...

This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $1,087,534.00 to the University of Washington to develop novel, synthetic therapies for stabilizing trauma victims in the critical "golden hour" after injury. The key objectives are to: 1) develop low-volume resuscitants that provide fluid...

This $8,042,749 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding research at The Ohio State University to enhance the safety and efficacy of low-titer Group O whole blood. The research involves determining optimal concentrations of hemopexin, haptoglobin, and transferrin to neutralize hemolytic byproducts during ex vivo storage of whole blood units. The project includes testing this protein...

The U.S. Defense Health Agency has awarded a $1,395,898 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Medicortex Finland LTD for the project titled "POINT-OF-INJURY DIAGNOSIS OF TRAUMATIC BRAIN INJURY USING SALIVA". The 2-year grant, effective from June 15, 2024 to June 14, 2026, will fund research to develop a point-of-injury diagnostic tool for traumatic brain injury using saliva samples. This aligns with the program's objective of...

This Project Grant award of $234,000.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Colorado-Denver to develop "hemostatic red blood cells" (T-RBCs) that can bind to collagen and fibrin to enhance clot formation and stability. The goal is to create a novel technology to address severe, non-compressible bleeding, which is a major cause of mortality worldwide, especially in low-resource settings. The...

This $309,279 Project Grant award, funded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a research study on traumatic brain injury (TBI) and psychological health conducted by Florida State University. The primary objectives are to adapt the Ohio State University TBI Identification Method and the STAIR-NT intervention for first responders with TBI, analyze the data, and disseminate the study findings. Key sub-award activities...

The Texas A&M Engineering Experiment Station (Tees) was awarded a $2,404,778 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research and development of expandable hemostats for treatment of noncompressible intracaivitary hemorrhage from August 15, 2022 to August 14, 2026. Through this funding, Tees will investigate medical solutions for uncontrolled bleeding on the battlefield,...

The federal Project Grant award in the amount of $783,715.00 was granted by the National Heart Lung and Blood Institute, part of the National Institutes of Health, under the Cardiovascular Diseases Research CFDA program (93.837). The award aims to improve the timeliness of care for trauma-induced hemorrhage by comprehensively determining who should be quickly transferred to specialized high-level trauma centers and evaluating state-of-the-art approaches to inform these retriage decisions. The...